Amendment: SEC Form SCHEDULE 13D/A filed by OS Therapies Incorporated

Item 4 of the Schedule 13D is hereby supplemented as follows: The Reporting Persons acquired and hold the securities described herein for investment purposes in the ordinary course of business and intend to review the investments in the Issuer on a continuing basis. The Reporting Persons acquired the securities described herein because they believed that the securities, when acquired, were undervalued and represented an attractive investment opportunity.

Item 5 of the Schedule 13D is hereby supplemented as follows: The information contained in rows 7, 8, 9, 10, 11 and 13 of the cover pages of this Amendment is hereby incorporated by reference in its entirety into this Item 5. As of the date hereof, Mr. Auerbach may be deemed to be the beneficial owner of an aggregate of 2,829,582 shares of Common Stock, all of which Mr. Auerbach has sole voting and dispositive power. The holdings of Mr. Auerbach represent an aggregate of approximately 12.9% of the Issuer's outstanding shares of Common Stock (based on 21,928,317 shares of Common Stock reported as outstanding as of January 28, 2025 in the Issuer's Registration Statement on Form S-1, filed with the SEC on January 31, 2025). As of the date hereof, Einodmil may be deemed to be the beneficial owner of an aggregate of 2,806,211 shares of Common Stock, all of which Einodmil has sole voting and dispositive power. The holdings of Einodmil represent an aggregate of approximately 12.8% of the Issuer's outstanding shares of Common Stock (based on 21,928,317 shares of Common Stock reported as outstanding as of January 28, 2025 in the Issuer's Registration Statement on Form S-1, filed with the SEC on January 31, 2025).

As of the date hereof, (i) Mr. Auerbach may be deemed to be the beneficial owner of an aggregate of 2,829,582 shares of Common Stock, all of which Mr. Auerbach has the sole voting and dispositive power, and (ii) Einodmil may be deemed to be the beneficial owner of an aggregate of 2,806,211 shares of Common Stock, all of which Einodmil has the sole voting and dispositive power.

During the period commencing sixty (60) days prior to the date hereof, (i) Einodmil sold 16,720 shares of Common Stock on January 15, 2025 pursuant to the Sales (as described in Item 3 of the Schedule 13D), which were effected on the open market at a weighted average price per share of approximately $6.735, (ii) Einodmil sold 100,000 shares of Common Stock on February 14, 2025 pursuant to the February 2025 Sales (as described in Item 3 of Amendment No. 1), which were effected on the open market at a weighted average price per share of approximately $2.843, and (iii) Einodmil received 375,000 shares of Common Stock on February 27, 2025 as a result of the Additional Transfer pursuant to the terms and conditions of the Transfer Agreement (as described in Item 3 and Item 4 of Amendment No. 1). Except for the foregoing, there were no other transactions by the Reporting Persons in shares of Common Stock during the period commencing sixty (60) days prior to the date hereof. Between July 31, 2024 (the date of event of the Schedule 13D) and January 17, 2025 (the filing date of the Schedule 13D), (i) Einodmil was issued 1,743,556 shares of Common Stock on August 2, 2024 as a result of Note Conversions in the aggregate principal amount of $3,270,000 (as described in Item 3 of the Schedule 13D), (ii) Mr. Auerbach was issued 23,371 shares of Common Stock on August 2, 2024 as a result of Note Conversions in the aggregate principal amount of $25,000 (as described in Item 3 of the Schedule 13D), and (iii) Einodmil sold 16,720 shares of Common Stock on January 15, 2025 pursuant to the Sales (as described in Item 3 of the Schedule 13D), which were effected on the open market at a weighted average price per share of approximately $6.735.

Exhibit 1 - Joint Filing Agreement, dated as of January 17, 2025, signed by each of the Reporting Persons, incorporated by reference to Exhibit 1 to the Schedule 13D. Exhibit 2 - Transfer Agreement, dated as of May 13, 2024, by and between Einodmil and Paul Romness, incorporated by reference to Exhibit 2 to the Schedule 13D.